0001104659-23-082362.txt : 20230719 0001104659-23-082362.hdr.sgml : 20230719 20230719163030 ACCESSION NUMBER: 0001104659-23-082362 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230710 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230719 DATE AS OF CHANGE: 20230719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Armata Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37544 FILM NUMBER: 231097030 BUSINESS ADDRESS: STREET 1: 4503 GLENCOE AVENUE CITY: MARINA DEL REY STATE: CA ZIP: 90292 BUSINESS PHONE: 310-665-2928 MAIL ADDRESS: STREET 1: 4503 GLENCOE AVENUE CITY: MARINA DEL REY STATE: CA ZIP: 90292 FORMER COMPANY: FORMER CONFORMED NAME: AmpliPhi Biosciences Corp DATE OF NAME CHANGE: 20130222 FORMER COMPANY: FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/ DATE OF NAME CHANGE: 19940331 8-K 1 tm2321631d1_8k.htm FORM 8-K
0000921114 false 0000921114 2023-07-10 2023-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 10, 2023

 

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

 

Washington   001-37544   91-1549568
(State or other jurisdiction
of incorporation or organization)		   (Commission File Number)   (IRS Employer Identification No.)

 

4503 Glencoe Avenue
 Marina del Rey, California		   90292
(Address of principal executive offices)   (Zip Code)

 

(310) 655-2928

(Registrant’s Telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock   ARMP   NYSE American

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) and Dr. Brian Varnum, the Company’s former Chief Executive Officer, entered into a separation and release agreement (the “Separation Agreement”).

 

Pursuant to the Separation Agreement, Dr. Varnum is entitled to (i) continued payment of his base salary for twelve (12) months following the date on which his employment with the Company terminated (which occurred on July 10, 2023) (the “Separation Date”) and (ii) subject to his timely election of COBRA coverage and continued enrollment in the Company’s health plan, payment of his and his covered dependents’ monthly COBRA premium cost for up to twelve (12) months following the Separation Date. Additionally, all unvested options held by Dr. Varnum that would have vested had his employment continued through the first anniversary of the Separation Date will vest and become exercisable on the first anniversary of the Separation Date and Dr. Varnum will have until September 30, 2024 (or the expiration date of the applicable option if earlier) to exercise any vested options. Dr. Varnum’s receipt of the foregoing payments and benefits is subject to his compliance with the Separation Agreement, including, without limitation, continued compliance with his existing restrictive covenants and the non-disparagement covenant set forth in the Separation Agreement.

 

The foregoing description of the Separation Agreement is qualified in its entirety by reference to the complete text of the Separation Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.

  

Description

10.1   Separation and Release Agreement, dated July 14, 2023.
104   Cover Page Interactive Data File (embedded within Inline XBRL document).

 

- 2 - 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 19, 2023 Armata Pharmaceuticals, Inc.
   
  By: /s/ Julianne Averill
  Name:  Julianne Averill
  Title: Chief Financial Officer

 

- 3 - 

 EX-10.1 2 tm2321631d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

Execution Version

 

SEPARATION AND RELEASE AGREEMENT

 

This Separation and Release Agreement (this “Agreement”), delivered July 10, 2023, confirms the following understandings and agreements between Armata Pharmaceuticals, Inc. (the “Company”) and Brian Varnum (hereinafter referred to as “you” or “your”).

 

In consideration of the promises set forth herein, you and the Company agree as follows:

 

1.                  Opportunity for Review; Acceptance.

 

(a)               You have until July 31, 2023 (the “Review Period”), to review and consider this Agreement. To accept this Agreement, and the terms and conditions contained herein, prior to the expiration of the Review Period, you must execute and date this Agreement where indicated below and return the executed copy of this Agreement to Kelly B. Holloway (the “Company Representative”), by email (kholloway@willkie.com). You acknowledge that, to the extent there are changes made to the terms of this Agreement, whether they are material or immaterial, the Review Period is not recommenced.

 

(b)               Notwithstanding anything contained herein to the contrary, this Agreement will not become effective or enforceable for a period of seven (7) calendar days following the date of your execution of this Agreement (the “Revocation Period”), during which time you may revoke your acceptance of this Agreement by notifying the Company Representative, in writing, as specified above. To be effective, such revocation must be received by the Company Representative no later than 5:00 p.m. Pacific Time on the seventh (7th) calendar day following your execution of this Agreement. Provided that this Agreement is executed during the Review Period, and you do not revoke it during the Revocation Period, the eighth (8th) day following the date on which this Agreement is executed and delivered to the Company shall be its effective date (the “Effective Date”). In the event that you fail to execute and deliver this Agreement prior to the expiration of the Review Period, this Agreement will be null and void and of no effect, and neither the Company nor any other member of the Company Group (as defined below) will have any obligations hereunder. In the event that you revoke this Agreement during the Revocation Period, this Agreement will be null and void and of no effect, and the Company will have no obligations hereunder.

 

2.                  Employment Status; Accrued Benefits; Separation Benefits.

 

(a)               Employment Status. You acknowledge and agree that your employment with the Company and its direct and indirect parent(s), subsidiaries, and affiliates (collectively, with the Company, the “Company Group”) terminated effective as of the close of business on July 10, 2023 (the “Separation Date”), and after the Separation Date, you will not represent yourself as being an employee, officer, agent, or representative of the Company or any other member of the Company Group. You hereby confirm your resignations from all offices, directorships, trusteeships, committee memberships and fiduciary and other capacities held with, or on behalf of, the Company Group (including, without limitation, as a member of the Company’s board of directors) effective as of the Separation Date and your execution of this Agreement will be deemed the grant by you to the officers of the Company of a limited power of attorney to sign in your name and on your behalf any such documentation as may be required to be executed solely for the limited purposes of effectuating such resignations. You agree that within five (5) business days following the Separation Date, you will update your accounts or profiles on any social media platform (including, but not limited to, Facebook, Twitter or LinkedIn) to reflect that you are no longer actively employed by or affiliated with the Company.

 

 

 

 

(b)               Accrued Benefits. The Separation Date shall be the termination date of your employment for purposes of participation in and coverage under all employee benefit plans and programs or arrangements sponsored by or through the Company and any other member of the Company Group, except as otherwise provided herein. You will be paid for (i) all of your earned but unpaid salary through the Separation Date on or prior to the Company’s next regularly scheduled payroll date on or following the Separation Date, or earlier to the extent otherwise required by applicable law, (ii) your accrued but unused vacation as of the Separation Date to the extent required by the Company’s policies, and (iii) any business expenses incurred prior to the Separation Date and properly submitted in accordance with the Company’s policies and procedures within ten (10) days following the Separation Date. In addition, thereafter you will be entitled to continued medical and health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), and additional information concerning such benefits will be provided to you under separate cover following the Separation Date.

 

(c)               Separation Benefits. In consideration of your release and waiver of claims set forth in paragraph ‎3 below, and subject to your execution, delivery and non-revocation of this Agreement and continued compliance with this Agreement, including but not limited to paragraph ‎10 hereof, the Company will provide you with the following separation payments and benefits (collectively, the “Consideration”):

 

(1)               Salary Continuation. Continued payment of your annual base salary for a period of twelve (12) months following the Separation Date (the “Severance Period”) in accordance with the Company’s regular payroll practices, except that no payments will be made prior to the thirtieth (30th) day following the Separation Date and, on the first regularly scheduled payroll date of the Company that is at least thirty (30) days following the Separation Date, the Company will pay you in a lump sum the amount of the Severance Pay that you would have received on or prior to such date under the original payment schedule but for the delay while waiting for the thirtieth (30th) day, with the balance of the Severance Pay being paid as originally scheduled;

 

(2)               COBRA Premiums. Subject to your timely election of COBRA continuation coverage and continuation of your enrollment under the Company’s group health insurance plan, on the first regularly scheduled payroll date of each month of the Severance Period, the Company will pay, directly to or on your behalf, an amount equal to the monthly COBRA premium cost for you and your covered dependents under such plan; provided, that the payments pursuant to this clause (2) shall cease earlier than the expiration of the Severance Term in the event that Executive becomes eligible to receive any health benefits, including through a spouse’s employer, during the Severance Period (which such eligibility shall be promptly reported by you to the Company); and

 

(3)               Equity Awards. Notwithstanding anything in the Company’s 2016 Equity Incentive Plan (the “Equity Plan”) or any applicable Award Agreement (as defined in the Equity Plan) to the contrary, (x) all unvested Options (as defined in the Equity Plan) held by you that would have vested had your employment continued through the first anniversary of the Separation Date (the “Unvested Options”) will remain outstanding and will vest and become exercisable on the first anniversary of the Separation Date subject to your continued compliance with this Agreement, including but not limited to paragraph ‎10 hereof through such date, and (y) the expiration date of any vested Options held by you as of the Separation Date and the Unvested Options will be extended until the earliest to occur of (i) September 30, 2024, (ii) the expiration date as set forth in the applicable Award Agreement governing such Options (without taking into account a termination of employment), and (iii) the date on which you breach any of your obligations pursuant to this Agreement, including but not limited to paragraph ‎10 hereof,

 

- 2 -

 

 

(d)               Deferral of Payments. Notwithstanding the foregoing, in the event that any amount would otherwise have been payable as a result of subparagraph ‎(c) above prior to the Effective Date, such amount shall not be paid until the first regular payroll date following the Effective Date.

 

(e)               Full Discharge. You acknowledge and agree that the payment(s) and other benefits provided pursuant to this paragraph ‎2 are in full discharge of any and all liabilities and obligations of the Company or any other member of the Company Group to you, monetarily or with respect to employee benefits or otherwise, including but not limited to any and all obligations arising under that certain employment agreement by and between you and the Company dated as of August 1, 2021, any other alleged written or oral employment agreement, policy, plan or procedure of the Company or any other member of the Company Group and/or any alleged understanding or arrangement between you and the Company or any other member of the Company Group (other than claims for accrued and vested benefits under an employee benefit, insurance, or pension plan of the Company or any other member of the Company Group (excluding any severance or similar plan or policy), subject to the terms and conditions of such plan(s)).

 

(f)                Taxes. Amounts provided hereunder, including without limitation the Consideration, are subject to withholding for all applicable taxes, including but not limited to income, employment, and social insurance taxes, as shall be required by law.

 

3.                  Release and Waiver of Claims.

 

(a)               As used in this Agreement, the term “claims” will include all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, accounts, attorneys’ fees, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise.

 

(b)               For and in consideration of the payments and benefits described in paragraph ‎2 above, and other good and valuable consideration, you, for and on behalf of yourself and your heirs, administrators, executors and assigns, as of the date hereof, do fully and forever release, remise and discharge each member of the Company Group and their successors and assigns, together with their respective officers, directors, partners, members, stockholders (including any management company of a stockholder), employees and agents (collectively, and with the Company, the “Company Parties”) from any and all claims whatsoever up to the date hereof which you had, may have had, or now have against the Company Parties, whether known or unknown, for or by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to your employment or the termination of your employment with the Company or any member of the Company Group, whether for tort, breach of express or implied employment contract, intentional infliction of emotional distress, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race, sex, national origin, handicap, religion, disability or sexual orientation. This release of claims includes, but is not limited to, all claims arising under the Age Discrimination in Employment Act (the “ADEA”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the Equal Pay Act, the Worker Adjustment and Retraining Notification Act, the Employee Retirement Income Security Act (excluding claims for accrued, vested benefits under an employee pension benefit plan of the Company Parties), the California Fair Employment and Housing Act, and the California Family Rights Act, each as may be amended from time to time, and all other federal, state and local laws, the common law and any other purported restriction on an employer’s right to terminate the employment of employees. You intend the release contained herein to be a general release of any and all claims to the fullest extent permissible by law and for the provisions regarding the release of claims against the Company Parties to be construed as broadly as possible, and hereby incorporate in this release similar federal, state or other laws, all of which you also hereby expressly waive.

 

- 3 -

 

 

(c)               You understand and agree that claims or facts in addition to or different from those which are now known or believed by you to exist may hereafter be discovered, but it is your intention to fully and forever release, remise and discharge all claims which you had, may have had, or now have against the Company Parties, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent or noncontingent, without regard to the subsequent discovery or existence of such additional or different facts. Without limiting the foregoing, by signing this Agreement, you expressly waive and release any provision of law that purports to limit the scope of a general release, including any and all rights and benefits under Section 1542 of the Civil Code of the State of California (or any analogous law of any other state, to the extent applicable), which provides as follows:

 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, AND THAT IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

 

(d)               You acknowledge and agree that as of the date you execute this Agreement, you have no knowledge of any facts or circumstances that give rise or could give rise to any claims under any of the laws listed in the preceding paragraphs.

 

(e)               Notwithstanding any provision of this Agreement to the contrary, by executing this Agreement, you are not releasing any claims relating to: (i) your rights with respect to payment of amounts under this Agreement, (ii) your right to accrued, vested benefits due to terminated employees under any employee benefit plan of the Company or any other member of the Company Group in which you participated (excluding any severance or similar plan or policy), in accordance with the terms thereof (including your right to elect COBRA continuation coverage), (iii) any claims that cannot be waived by law or that arise after the date on which you execute this Agreement; (iv) your right to indemnification, advancement and reimbursement of legal fees and expenses, and directors and officers liability insurance, as provided by, and in accordance with the terms of, applicable law, the Company’s by-laws or otherwise; or (v) any rights or claims under the ADEA that may arise after the date that you execute this Agreement.

 

(f)                You acknowledge and agree that, by virtue of the foregoing, you have waived any relief available to you (including without limitation, monetary damages, equitable relief and reinstatement) under any of the claims and/or causes of action waived in this paragraph ‎3. Therefore you agree that you will not accept any award or settlement from any source or proceeding (including but not limited to any proceeding brought by any other person or by any government agency) with respect to any claim or right waived in this Agreement.

 

(g)               You acknowledge and agree that as of the date of this Agreement, you have reported all accidents, injuries or illnesses relating to or arising from your employment with the Company or the Company Group and that you have not suffered any on-the-job injury or illness for which you have not yet filed a claim.

 

4.                  Knowing and Voluntary Waiver. You expressly acknowledge and agree that you:

 

(a)               are able to read the language, and understand the meaning and effect, of this Agreement;

 

(b)              have no physical or mental impairment of any kind that has interfered with your ability to read and understand the meaning of this Agreement or its terms, and that you are not acting under the influence of any medication, drug or chemical of any type in entering into this Agreement;

 

(c)               are specifically agreeing to the terms of the release contained in this Agreement because the Company has agreed to provide you the Consideration, which the Company has agreed to provide because of your agreement to accept it in full settlement of all possible claims you might have or ever had, and because of your execution of this Agreement;

 

(d)               acknowledge that but for your execution of this Agreement, you would not be entitled to the Consideration;

 

(e)               had or could have the entire Review Period in which to review and consider this Agreement and that if you execute this Agreement prior to the expiration of the Review Period, you have voluntarily and knowingly waived the remainder of the Review Period;

 

- 4 -

 

 

(f)                understand that, by entering into this Agreement, you do not waive rights or claims under the ADEA that may arise after the date you execute this Agreement;

 

(g)               have not relied upon any representation or statement not set forth in this Agreement made by the Company Group or any of its representatives;

 

(h)               were advised to consult with your attorney regarding the terms and effect of this Agreement; and

 

(i)                 have signed this Agreement knowingly and voluntarily.

 

5.                  No Suit. You represent and warrant that you have not previously filed, and to the maximum extent permitted by law agree that you will not file, a complaint, charge or lawsuit against any of the Company Parties regarding any of the claims released herein. If, notwithstanding this representation and warranty, you have filed or file such a complaint, charge or lawsuit, you agree that you shall cause such complaint, charge or lawsuit to be dismissed with prejudice and shall pay any and all costs required in obtaining dismissal of such complaint, charge or lawsuit, including without limitation the attorneys’ fees of any of the Company Parties against whom you have filed such a complaint, charge, or lawsuit. This paragraph ‎5 shall not apply, however, to any non-waivable right to file a charge with the U.S. Equal Employment Opportunity Commission (the “EEOC”) or similar state agency; provided, however, that if the EEOC or similar state agency pursues any claims relating to your employment with the Company or any member of the Company Group, you agree that you shall not be entitled to recover any monetary damages or any other remedies or benefits as a result and that this Agreement and the Consideration will control as the exclusive remedy and full settlement of all such claims by you.

 

6.                  Successors and Assigns. The provisions hereof shall inure to the benefit of your heirs, executors, administrators, legal personal representatives and assigns and shall be binding upon your heirs, executors, administrators, legal personal representatives and assigns.

 

7.                  Severability; Third-Party Beneficiaries. If any provision of this Agreement shall be held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect. The illegality or unenforceability of such provision, however, shall have no effect upon and shall not impair the enforceability of any other provision of this Agreement. You acknowledge and agree that each of the Company Parties shall be a third-party beneficiary of the releases set forth in paragraph ‎3 above, with full rights to enforce this Agreement and the matters documented herein.

 

8.                  Non-Disparagement. You agree that you will make no disparaging or defamatory comments regarding any member of the Company Group or their respective current or former directors, officers, employees, members, stockholders (including any management company of a stockholder), or affiliates in any respect or make any comments concerning any aspect of your relationship with any member of the Company Group or the conduct or events which precipitated your termination of employment from any member of the Company Group. Your obligations under this paragraph ‎8 extend to, but are not limited to, text messages, e-mail communications, and comments or postings on blogs, comment boards or social media websites including, but not limited to, Facebook, Twitter or LinkedIn. Further, nothing in this Agreement prohibits you from speaking with law enforcement, the Equal Employment Opportunity Commission, any state or local division of human rights or fair employment agency, or your attorney. This paragraph ‎8 shall not prevent the truthful testimony by any individual or entity in a legal proceeding or pursuant to a governmental, administrative or regulatory investigation.

 

- 5 -

 

 

9.                  Cooperation.

 

(a)               You agree that you will provide reasonable cooperation to the Company and/or any other member of the Company Group and its or their respective counsel in connection with any investigation, administrative proceeding or litigation relating to any matter that occurred during your employment in which you were involved or of which you have knowledge. The Company agrees to reimburse you for reasonable out-of-pocket expenses incurred at the request of the Company with respect to your compliance with this paragraph ‎9(a).

 

(b)               You agree that, in the event you are subpoenaed by any person or entity (including, but not limited to, any government agency) to give testimony or provide documents (in a deposition, court proceeding or otherwise) which in any way relates to your employment by the Company and/or any other member of the Company Group, you will give prompt written notice of such request to the Chief Executive Officer of the Company, in writing and will make no disclosure until the Company and/or the other member of the Company Group has had a reasonable opportunity to contest the right of the requesting person or entity to such disclosure. The Company agrees to reimburse you for reasonable out-of-pocket expenses incurred at the request of the Company with respect to your compliance with this paragraph ‎9(b).

 

10.           Affirmation of Continuing Obligations. You hereby acknowledge and agree that the execution of this Agreement does not alter your obligations to any member of the Company Group under any confidentiality, non-solicit, invention assignment, or similar agreement or arrangement to which you are a party with any member of the Company Group (the “Continuing Obligations”), which obligations are hereby incorporated into this Agreement and shall survive the termination of your employment with the Company, and you hereby acknowledge, reaffirm and ratify your continuing obligations to the Company Group pursuant to such agreements or arrangements. You further hereby acknowledge that your continued compliance with these obligations is a condition of your receiving the Consideration described in paragraph ‎2 above and upon any breach of the Continuing Obligations, the Company shall be entitled to an immediate refund of any Consideration already received by you.

 

11.           Confidentiality. The terms and conditions of this Agreement are and shall be deemed to be confidential, and shall not be disclosed by you to any person or entity without the prior written consent of the Company, except if required by law, and to your accountants, attorneys and/or immediate family, provided that, to the maximum extent permitted by applicable law, rule, code or regulation, they agree to maintain the confidentiality of this Agreement.

 

12.           Return of Property. You agree that you will promptly return to the Company, and you will retain no copies of, all property belonging to the Company and/or any other member of the Company Group, including but not limited to all proprietary and/or confidential information and documents (including any copies thereof) in any form belonging to the Company, cell phone, Blackberry, iPhone or other mobile device, keys, credit card, identification card or badge, access card, employee handbook, laptop, computer or other office equipment, computer user name and password, disks, data files, thumb drives, and/or voicemail code. If you discover after the Separation Date that you have retained any proprietary and/or confidential information (including, without limitation, proprietary and/or confidential information contained in any electronic documents or email systems in your possession or control), you agree immediately upon discovery to send an email to the Chief Executive Officer of the Company to inform the Company of the nature and location of the proprietary and/or confidential information that you have retained so that the Company may arrange to remove, recover, and/or collect such information. You further acknowledge and agree that the Company shall have no obligation to provide the Consideration described in paragraph ‎2 above unless and until you have satisfied all your obligations pursuant to this paragraph ‎12.

 

- 6 -

 

 

13.              Non-Admission. Nothing contained in this Agreement will be deemed or construed as an admission of wrongdoing or liability on the part of you or any member of the Company Group. Accordingly, this Agreement may not be admissible in any forum as an admission, but only in an action to enforce it.

 

14.              Entire Agreement. This Agreement and the Continuing Obligations constitute the entire understanding and agreement of the parties hereto regarding the termination of your employment. This Agreement and the Continuing Obligations supersede all prior negotiations, discussions, correspondence, communications, understandings and agreements between the parties relating to the subject matter of this Agreement and the Continuing Obligations .

 

15.              Attorneys’ Fees and Costs. You hereby acknowledge and agree that the Company Parties are entitled to recover from you all reasonable attorneys’ fees and costs associated with their efforts to enforce this Agreement or the Continuing Obligations and/or to recover damages for a breach of this Agreement or the Continuing Obligations by you, and/or which are incurred by the Company Parties as a result of a breach of this Agreement or the Continuing Obligations by you.

 

16.              Governing Law; Jurisdiction; Arbitration. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH FEDERAL LAW AND THE LAWS OF THE STATE OF CALIFORNIA, APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES. BY EXECUTION OF THIS AGREEMENT, EACH PARTY TO THIS AGREEMENT HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF CALIFORNIA AND HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY IN CONNECTION WITH ANY DISPUTE ARISING UNDER OR CONCERNING THIS AGREEMENT. ALL DISPUTES ARISING UNDER OR CONCERNING THIS AGREEMENT, AS WELL AS ALL CLAIMS ARISING OUT OF YOUR EMPLOYMENT OR TERMINATION THEREOF, INCLUDING WITHOUT LIMITATION ALL CLAIMS FOR PAYMENT OF WAGES, DISCRIMINATION, RETALIATION, AND ALL OTHER CLAIMS BASED ON ANY STATE, FEDERAL OR COMMON LAW WILL BE RESOLVED THROUGH BINDING ARBITRATION BEFORE A SINGLE ARBITRATOR. THE ARBITRATION SHALL BE ADMINISTERED BY JAMS, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. IF JAMS CANNOT SERVE AS THE ARBITRATION ADMINISTRATOR, THEN THE ARBITRATION WILL BE THROUGH THE AMERICAN ARBITRATION ASSOCIATION, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. THE EXCLUSIVE VENUE OF ANY SUCH ARBITRATION WILL BE Los angeles, california. THE NON-PREVAILING PARTY WILL PAY THE REASONABLE ATTORNEYS’ FEES AND COSTS OF THE PREVAILING PARTY. THE ARBITRATOR SHALL HAVE AUTHORITY TO ISSUE EQUITABLE AND LEGAL RELIEF, INCLUDING WITHOUT LIMITATION INJUNCTIVE RELIEF AND MONETARY DAMAGES. ALL ARBITRATION PROCEEDINGS SHALL BE CONFIDENTIAL.

 

17.              Construction. The section or paragraph headings or titles herein are for convenience of reference only and shall not be deemed a part of this Agreement. The parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions of this Agreement and has had the opportunity to contribute to its revision. Accordingly, the rule of construction to the effect that ambiguities are resolved against the drafting party, including, but not limited to Section 1654 of the California Civil Code, shall not be employed in the interpretation of this Agreement. Rather, the terms of this Agreement shall be construed in a reasonable manner to effect the intentions of both parties hereto and not in favor or against either party.

 

18.              Section 409A. Payments under this Agreement are intended to be exempt from, or comply with, Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), and this Agreement will be interpreted to achieve this result. For purposes of this Agreement, each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no event is the Company responsible for any tax or penalty owed by you (other than for withholding obligations or other obligations applicable to employers, if any, under Section 409A) with respect to payments under this Agreement.

 

19.              Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument, and electronically delivered copies of executed counterparts shall be deemed to be originals for all purposes.

 

*        *        *

 

- 7 -

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth below.

 

  ARMATA PHARMACEUTICALS, INC.
     
  By: /s/ Robin C. Kramer
    Robin C. Kramer
    Chair, Board of Directors
   
  EMPLOYEE
   
  /s/ Brian Varnum
  BRIAN VARNUM, Ph.D
   
  Dated: July 14, 2023

 

[Signature Page to Brian Varnum Separation Agreement]

 

 

 

 EX-101.SCH 3 armp-20230710.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 armp-20230710_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 armp-20230710_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 10, 2023
Entity File Number 001-37544
Entity Registrant Name ARMATA PHARMACEUTICALS, INC.
Entity Central Index Key 0000921114
Entity Tax Identification Number 91-1549568
Entity Incorporation, State or Country Code WA
Entity Address, Address Line One 4503 Glencoe Avenue
Entity Address, City or Town Marina del Rey
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90292
City Area Code 310
Local Phone Number 655-2928
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ARMP
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 7 tm2321631d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000921114 2023-07-10 2023-07-10 iso4217:USD shares iso4217:USD shares 0000921114 false 8-K 2023-07-10 ARMATA PHARMACEUTICALS, INC. WA 001-37544 91-1549568 4503 Glencoe Avenue Marina del Rey CA 90292 310 655-2928 false false false false false Common Stock ARMP NYSEAMER EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://armatapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2321631d1_8k.htm armp-20230710.xsd armp-20230710_lab.xml armp-20230710_pre.xml tm2321631d1_ex10-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2321631d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2321631d1_8k.htm" ] }, "labelLink": { "local": [ "armp-20230710_lab.xml" ] }, "presentationLink": { "local": [ "armp-20230710_pre.xml" ] }, "schema": { "local": [ "armp-20230710.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "armp", "nsuri": "http://armatapharma.com/20230710", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2321631d1_8k.htm", "contextRef": "AsOf2023-07-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://armatapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2321631d1_8k.htm", "contextRef": "AsOf2023-07-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-082362-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-082362-xbrl.zip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end